{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:53:24Z","timestamp":1790481204529,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013731","name":"Shell United States","doi-asserted-by":"publisher","award":["1R01CA200844"],"award-info":[{"award-number":["1R01CA200844"]}],"id":[{"id":"10.13039\/100013731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ejpb.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T21:25:54Z","timestamp":1546982754000},"page":"18-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-9882","authenticated-orcid":false,"given":"Jiayi","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia P.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Filipczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Garai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh A.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Sarisozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir P.","family":"Torchilin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpb.2019.01.006_b0005","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40005-016-0296-2","article-title":"Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors","volume":"47","author":"Sarisozen","year":"2017","journal-title":"J. Pharm. Invest."},{"issue":"11","key":"10.1016\/j.ejpb.2019.01.006_b0015","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ejpb.2019.01.006_b0020","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.107.015354","article-title":"Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17","volume":"35","author":"Shen","year":"2007","journal-title":"Drug. Metab. Dispos."},{"issue":"47","key":"10.1016\/j.ejpb.2019.01.006_b0025","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejpb.2019.01.006_b0030","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-05-2130","article-title":"Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer","volume":"12","author":"Gagnon","year":"2006","journal-title":"Clin. Can. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/86.1.18","article-title":"Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer","volume":"86","author":"Kohn","year":"1994","journal-title":"J. Natl. Can. Inst."},{"issue":"6","key":"10.1016\/j.ejpb.2019.01.006_b0040","first-page":"1311","article-title":"Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines","volume":"63","author":"Selvakumaran","year":"2003","journal-title":"Can. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0045","first-page":"1","article-title":"The role of DNA mismatch repair in drug resistance","volume":"4","author":"Fink","year":"1998","journal-title":"Clin. Can. Res."},{"issue":"53","key":"10.1016\/j.ejpb.2019.01.006_b0050","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","article-title":"Survivin, versatile modulation of cell division and apoptosis in cancer","volume":"22","author":"Altieri","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2019.01.006_b0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-60761-416-6_4","article-title":"Mechanisms of multidrug resistance in cancer","volume":"596","author":"Gillet","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.ejpb.2019.01.006_b0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.cgt.7700706","article-title":"Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells","volume":"11","author":"Lima","year":"2004","journal-title":"Can. Gene. Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1073\/pnas.84.1.265","article-title":"Expression of a multidrug-resistance gene in human tumors and tissues","volume":"84","author":"Fojo","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","article-title":"Expression of a multidrug resistance gene in human cancers","volume":"81","author":"Goldstein","year":"1989","journal-title":"J. Natl. Can. Inst."},{"issue":"5","key":"10.1016\/j.ejpb.2019.01.006_b0075","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/07357900801904140","article-title":"Expression of multidrug resistance genes in normal and cancer stem cells","volume":"26","author":"Shervington","year":"2008","journal-title":"Can. Invest."},{"issue":"5","key":"10.1016\/j.ejpb.2019.01.006_b0080","first-page":"1949","article-title":"Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump","volume":"6","author":"Goren","year":"2000","journal-title":"Clin. Can. Res."},{"issue":"18","key":"10.1016\/j.ejpb.2019.01.006_b0085","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Can. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2019.01.006_b0090","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood.V80.5.1158.1158","article-title":"Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia","volume":"80","author":"Trippett","year":"1992","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejpb.2019.01.006_b0095","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/0959-8049(94)90132-5","article-title":"Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers","volume":"30A","author":"Veneroni","year":"1994","journal-title":"Eur. J. Can."},{"issue":"3","key":"10.1016\/j.ejpb.2019.01.006_b0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JCO.1985.3.3.311","article-title":"Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance","volume":"3","author":"Bell","year":"1985","journal-title":"J. Clin. Oncol."},{"issue":"3 Pt 1","key":"10.1016\/j.ejpb.2019.01.006_b0105","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1158\/1078-0432.CCR-05-0950","article-title":"mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T\/A correlates with response to paclitaxel chemotherapy","volume":"12","author":"Green","year":"2006","journal-title":"Clin. Can. Res."},{"issue":"7","key":"10.1016\/j.ejpb.2019.01.006_b0110","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/oxfordjournals.annonc.a059284","article-title":"Prognostic relevance of P-glycoprotein expression in breast cancer","volume":"6","author":"Linn","year":"1995","journal-title":"Ann. Oncol."},{"issue":"2B","key":"10.1016\/j.ejpb.2019.01.006_b0115","first-page":"1061","article-title":"P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer","volume":"20","author":"Baekelandt","year":"2000","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2006.07.020","article-title":"Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance","volume":"173","author":"Yabuki","year":"2007","journal-title":"Can. Genet. Cytogenet."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2019.01.006_b0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drup.2012.02.002","article-title":"Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies","volume":"15","author":"Amiri-Kordestani","year":"2012","journal-title":"Drug Resist. Updat."},{"issue":"7","key":"10.1016\/j.ejpb.2019.01.006_b0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2174\/138945006777709566","article-title":"MDR1\/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance","volume":"7","author":"Lage","year":"2006","journal-title":"Curr. Drug. Targets"},{"key":"10.1016\/j.ejpb.2019.01.006_b0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-1-60761-416-6_20","article-title":"Overcoming multidrug resistance by RNA interference","volume":"596","author":"Stege","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"27","key":"10.1016\/j.ejpb.2019.01.006_b0140","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1016\/j.biomaterials.2012.05.039","article-title":"Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters)","volume":"33","author":"Yin","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ejpb.2019.01.006_b0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2009.08.013","article-title":"Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel","volume":"140","author":"Liu","year":"2009","journal-title":"J. Control Release"},{"issue":"23","key":"10.1016\/j.ejpb.2019.01.006_b0150","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1002\/cncr.25321","article-title":"Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells","volume":"116","author":"Abbasi","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejpb.2019.01.006_b0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00280-008-0790-y","article-title":"Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells","volume":"63","author":"Yadav","year":"2009","journal-title":"Can. Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejpb.2019.01.006_b0160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jconrel.2009.06.019","article-title":"Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery","volume":"140","author":"Taratula","year":"2009","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0165","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/bc200433s","article-title":"SiRNA delivery systems based on neutral cross-linked dendrimers","volume":"23","author":"Liu","year":"2012","journal-title":"Bioconjugate Chem."},{"issue":"10","key":"10.1016\/j.ejpb.2019.01.006_b0170","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/bc900228m","article-title":"PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma","volume":"20","author":"Waite","year":"2009","journal-title":"Bioconjugate Chem."},{"issue":"6","key":"10.1016\/j.ejpb.2019.01.006_b0175","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1021\/mp200654g","article-title":"Potential use of lactosylated dendrimer (G3)\/alpha-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy","volume":"9","author":"Hayashi","year":"2012","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2019.01.006_b0180","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/mp3001364","article-title":"Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers","volume":"9","author":"Tang","year":"2012","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.ejpb.2019.01.006_b0185","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1021\/ma0106346","article-title":"Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible. High-efficiency DNA delivery","volume":"35","author":"Luo","year":"2002","journal-title":"Macromolecules"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/bm8009973","article-title":"Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting","volume":"10","author":"Patil","year":"2009","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0195","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.biomaterials.2009.09.048","article-title":"The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance","volume":"31","author":"Patil","year":"2010","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.ejpb.2019.01.006_b0200","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nmat1737","article-title":"Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer","volume":"5","author":"Wang","year":"2006","journal-title":"Nat Mater"},{"issue":"29","key":"10.1016\/j.ejpb.2019.01.006_b0205","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1074\/jbc.M110.125906","article-title":"Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer","volume":"285","author":"Chen","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.ejpb.2019.01.006_b0210","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/smll.200900621","article-title":"Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells","volume":"5","author":"Chen","year":"2009","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0215","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1021\/nn103349h","article-title":"Simultaneous delivery of siRNA and paclitaxel via a \u201ctwo-in-one\u201d micelleplex promotes synergistic tumor suppression","volume":"5","author":"Sun","year":"2011","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ejpb.2019.01.006_b0220","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1021\/nn2013707","article-title":"Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin","volume":"5","author":"Xiong","year":"2011","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.ejpb.2019.01.006_b0225","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.biomaterials.2012.10.024","article-title":"Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery","volume":"34","author":"Biswas","year":"2013","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/nnm.11.93","article-title":"P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells","volume":"7","author":"Navarro","year":"2012","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"10.1016\/j.ejpb.2019.01.006_b0235","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/la00063a015","article-title":"Fluorescence probes for critical micelle concentration determination","volume":"1","author":"Goddard","year":"1985","journal-title":"Langmuir"},{"issue":"15","key":"10.1016\/j.ejpb.2019.01.006_b0240","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.1021\/la201882t","article-title":"Analysis of poly(amidoamine) dendrimer structure by UV-vis spectroscopy","volume":"27","author":"Pande","year":"2011","journal-title":"Langmuir"},{"issue":"11","key":"10.1016\/j.ejpb.2019.01.006_b0245","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1073\/pnas.91.11.4654","article-title":"Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane","volume":"91","author":"Altenberg","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0250","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/nnm.10.122","article-title":"Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats","volume":"6","author":"Lankveld","year":"2011","journal-title":"Nanomedicine (Lond)"},{"issue":"14","key":"10.1016\/j.ejpb.2019.01.006_b0255","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1016\/j.biomaterials.2010.01.089","article-title":"Folate-PEG coated cationic modified chitosan\u2013cholesterol liposomes for tumor-targeted drug delivery","volume":"31","author":"Wang","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0260","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.colsurfb.2006.02.006","article-title":"A reduction-triggered delivery by a liposomal carrier possessing membrane-permeable ligands and a detachable coating","volume":"49","author":"Maeda","year":"2006","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11095-007-9348-7","article-title":"Sheddable coatings for long-circulating nanoparticles","volume":"25","author":"Romberg","year":"2008","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2019.01.006_b0270","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0005-2736(98)00175-8","article-title":"Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient","volume":"1415","author":"Li","year":"1998","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.ejpb.2019.01.006_b0275","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.2147\/IJN.S141229","article-title":"Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer","volume":"12","author":"Zhou","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"17","key":"10.1016\/j.ejpb.2019.01.006_b0280","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2217\/nnm-2017-0178","article-title":"Plasma protein adsorption and biological identity of systemically administered nanoparticles","volume":"12","author":"Chen","year":"2017","journal-title":"Nanomedicine (Lond)"},{"issue":"2","key":"10.1016\/j.ejpb.2019.01.006_b0285","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0005-2728(01)00165-7","article-title":"p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups","volume":"1511","author":"Torchilin","year":"2001","journal-title":"Biochim. Biophys. Acta"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118312177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118312177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:32:00Z","timestamp":1760545920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118312177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":57,"alternative-id":["S0939641118312177"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.01.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}